1. Novel Drugs Approvals for 2022: Mounjaro™ (tirzepatide).;FDA online.
2. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes.;FDA online.,2022
3. FDA Approves Lilly’s Mounjaro™ (Tirzepatide) Injection, The First and Only GIP And GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes.,2022
4. National Diabetes Statistics Report.;CDC online.,2022
5. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial.;Lancet.,2021